CD68 and cardiac hypertrophy: In particular, enhancement of TLR4 signaling has been reported to trigger ROS production, inflammation and CD68+ macrophage infiltration, leading to cardiac hypertrophy, fibrosis and HF, whereas administration of TLR4 antagonist prevented cardiac hypertrophy and dysfunction [63].